Drug Profile
Alpha melanotropin - RELIEF THERAPEUTICS Holding
Alternative Names: Alpha-msh - mondoBIOTECH; DasKloster 0210-01; DasKloster0210; DK 0210Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Class Melanocyte-stimulating hormones
- Mechanism of Action T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Berylliosis
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Berylliosis in Switzerland (Parenteral) (RELIEF THERAPEUTICS Holding pipeline, February 2023)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Berylliosis in Switzerland (Parenteral)
- 31 Jul 2016 Preclinical development is ongoing in Beryllisis Switzerland